Skip to main content
Journal of the American Society of Nephrology : JASN logoLink to Journal of the American Society of Nephrology : JASN
editorial
. 2016 Apr 20;27(10):2919–2921. doi: 10.1681/ASN.2016030344

Prorenin Receptor, a Necessary Component in Urine Concentration Mechanism

Boye L Jensen 1,
PMCID: PMC5042682  PMID: 27098238

In this issue of the Journal of the American Society of Nephrology (JASN), Wang et al.1 unravel an intriguing new signaling cascade that involves the prorenin receptor (PRR) in the kidney collecting ducts (CDs) as a necessary component of the physiologic ability of the kidneys to concentrate urine. The pathway includes serial coupling between the vasopressin (AVP) V2 receptor, the prostaglandin E2 (PGE2) EP4 receptor, and PRR, all associated with CDs. Many factors are known to modulate urine concentration—both hormones, like angiotensin II, aldosterone, cortisol, and endothelin and paracrine factors, like ATP—whereas few are true mediators. It is fascinating to uncover what seems to be a new and nonredundant mediator pathway downstream from the AVP V2 receptor. Here, at the intrarenal level, the findings indicate hierarchical interpositions of local PGE2 EP4 receptor–driven renin/prorenin-PRR interaction as necessary sequential mediators for the AVP V2 effect on CD transepithelial water transport.

The PRR was cloned in 2002 by Nguyen et al.2 In its native form, it is a 35-kD protein that undergoes intracellular proteolysis. This gives rise to a full–length membrane integral form and a soluble PRR. The soluble form is cleaved by intracellular proprotein convertase/serine endoprotease furin and released into plasma and urine with the ability to bind renin and activate prorenin.3 Finally, a truncated form is associated with the vacuolar H+-ATPase,4 with activity that is enhanced by prorenin.5 PRR ligands comprise prorenin and active renin, with proteolytic activities that are enhanced by binding.2 In the kidney, PRR is predominantly associated with the CDs and the distal nephron.6 The PRR is most abundant in microvilli at the apical surface of A–type intercalated cells.6 Several groups have, in parallel studies, contributed converging observations on renal PRR and thus, bits to the puzzle. A prequel paper was published in October of 2015 showing the effect of nephron-specific deletion of PRR.7 The phenotype was nephrogenic diabetes insipidus with lower levels of the apical water transport protein AQP2 in kidney tissue and impaired AVP V2 receptor–induced cAMP formation in medulla tissue.7 Impaired vasopressin signaling with attenuated cAMP formation had already been shown in vitro after siRNA depletion of PRR in MDCK cells.5 On the basis of this, PRR seemed to be necessary for AVP signaling in principal cells of CDs and thus, baseline urine concentration. Previous data supported the observation indirectly, because Cp2l1tra/tra (Grainyhead transcription factor) mice, which lacked type A–intercalated cells (that express PRR) in CDs, displayed mild polyuria.8 What were the mechanisms by which PRR promoted cAMP signaling and the link to normal physiology? A physiologic role for PGs in the regulation of PRR was indicated by the observation that stimulation of medullary PRR and renin by angiotensin II depended on a PGE2 EP4 receptor.9 An unequivocal function for the PGE2 EP4 receptor in renal water handling was shown in 2015.10 The EP4 receptor couples to a Gs protein, leading to adenylate cyclase stimulation and formation of cAMP. In the kidney, the EP4 receptor is associated with CDs, glomeruli, and renal resistance vessels.1113 Although first observations in mice with global EP4 receptor deletion showed a mild diuresis only after low salt intake, no electrolyte disturbances, and impaired renin release from juxtaglomerular cells,14,15 the 2015 data indicated that EP4 receptors were physiologically stimulated by water deprivation in renal medulla.10 Moreover, renal tubule– and CD–specific EP4 receptor deletion resulted in increased baseline diuresis, normal electrolyte excretion, impaired urine concentrating ability with attenuated AQP2 protein abundance, and impaired cAMP formation but intact circulating levels of AVP.10 Thus, similar to CD–specific PRR deletion, the CD EP4–deleted phenotype exhibited nephrogenic insipidus. This observation provided a mechanistic clue to the previous observations that, in experimental nephrogenic diabetes insipidus models in rats and mice, EP4 receptor agonists alleviated increased diuresis16,17 Similar to the PRR, EP4 receptor seems necessary for baseline renal water conservation and urine concentration ability through an intrarenal mechanism. This article by Wang et al.1 takes off at this site with putative roles for CD EP4 receptor and PRR in urine concentration and shows their interaction by a series of complementary pharmacologic and genetic in vivo and in vitro intervention approaches.

Water deprivation stimulated intercalated cell production of PRR, release of soluble PRR, and prorenin protein and mRNA abundance in medulla tissue and renin in urine but not plasma. Both PRR and renin stimulation depended on the EP4 receptor.1 Intrarenal infusion of PRR antagonist attenuated physiologic urine concentrating ability and medullary AQP2 protein level,1 showing the dynamic nature of the response and ruling out nonspecific effects in published murine models with targeted deletion of PRR. Moreover, the putative in vivo stimulatory response of prorenin on AQP2 was robust; it could be reproduced in vitro by addition of nanomolar prorenin concentrations to primary cultured rat CD cells, and three independent ways of inhibiting/deleting the PRR receptor abolished the response.1 More importantly, the response of AQP2 to AVP and EP4 receptor agonist stimulation in vitro was inhibited similarly by the inhibitory PRR protocols. Together, these data established PRR as a relevant common regulator of AQP2 protein abundance downstream of AVP V2 and EP4 signaling.

The paper by Wang et al.1 in this issue of the JASN corroborated a necessary role for EP4 in AVP signaling and AQP2 stimulation. In addition, it showed that EP4 antagonism abrogated the intrarenal renin response to water deprivation/AVP stimulation, which suggests that PGE2 through EP4 receptor drives intrarenal CD prorenin/renin expression and release, much like the role for EP4 receptor in the juxtaglomerular cells.15 The paper by Wang et al.1 also presents mice with a CD-specific deletion of PRR that displayed a nephrogenic diabetes insipidus phenotype as in the work by Ramkumar et al.,7 but important additional information was reported. Increased urine renin activity after water deprivation was abrogated, suggesting that PRR is, indeed, contributing to water deprivation–induced tubular renin activation. An attempt to merge these findings into a physiologic cascade could include the following steps. In conditions of water deprivation, the AVP V2 signal contributes to local medullary PGE2 synthesis—both directly as shown in this paper1 and likely indirectly through elevated interstitial osmolality, which enhances cyclooxygenase-2 (COX-2) activity in medullary interstitial cells.18,19 COX-2 activity leads to PGE2 release and stimulates local EP4 receptor and medullary synthesis of prorenin and PRR.20 Prorenin is next released and stimulates PRR to enhance AQP2 abundance. The intracellular mechanisms by which PRR transduces ligand binding to control AQP2 are not elucidated in the study by Wang et al.1 Also, the role for interstitial hypertonicity in the reported responses is not clear. Finally, the question appears of why the renin inhibitor aliskiren in clinical use and the common over the counter painkiller NSAIDs do not impair urine concentration, because the findings by Wang et al.1 imply nonredundant mechanisms? First, studies have shown that renin and prorenin with active sites blocked by aliskiren do not display impaired binding and activation of PRR.21 Second, because both COX-1 and -2 are highly expressed in the medulla and because NSAIDs display variable selectivity, there is likely sufficient PGE2 to support the mechanism, despite NSAID intake. In support of this, experiments in rats given both COX-1 and -2 blockers in separate series showed no measurable change in urine PGE2 excretion while dehydration–induced AQP2 upregulation was inhibited, completely in line with the findings by Wang et al.1 in this issue of the JASN.22 Moreover, mice with phospholipase A2 deletion that is upstream of COX enzymes and therefore, broadly lowers prostanoid synthesis, in fact, display impaired urine concentration,23 which was also observed in COX-2−/− mice.24 In contrast, mPGE synthase deletion did not abrogate but enhanced urine concentration.25 Some opposing findings clearly await additional experimentation. Along this line, PRR is associated with intercalated cells,6 but AQP2 is found in principal cells. How is the renin/prorenin-PRR response then transmitted? Because renin/prorenin of CD origin is released to urine and not measurably released to plasma, is the response via the apical membrane where PRR is found in microvilli? And if so, in proteinuria, how can local renin/prorenin signals not be overridden by luminal pro(renin)? What are the perspectives of these findings? Nephrogenic diabetes insipidus can be acquired, which is the case with chronic lithium ingestion, and can be inherited, which is caused typically by X–linked loss-of-function mutations in the V2 receptor gene, and the disease can be seriously debilitating because of the large urine volume and constant need to drink large volumes. Little can currently be done to help these patients, and both EP4 agonists and PRR agonism are attractive ways to stimulate CDs and bypass defect V2 receptor function. It shall be interesting to follow the development in coming years, and the work by Wang et al.1 sets the stage for many new hypotheses.

Disclosures

Research in the authors lab is supported by the Danish Research Council for Health and Disease, The Danish Heart Association and The Strategic Research Council.

Acknowledgments

Prof. Pernille B.L. Hansen is thanked for critical reading of the manuscript.

Footnotes

Published online ahead of print. Publication date available at www.jasn.org.

See related article, “Antidiuretic Action of Collecting Duct (Pro)Renin Receptor Downstream of Vasopressin and PGE2 Receptor EP4,” on pages 3022–3034.

References

  • 1.Wang F, X L, Kexin Peng, Hui Fang, Li Zhou, Jiahui Su, Adam Nau, Kevin Yang, Atsuhiro Ichihara, Aihua Lu, Shu-Feng Zhou, Tianxin Yang: Defining antidiuretic action of collecting duct (pro)renin receptor. I. Interaction with vasopressin/prostaglandin EP4 receptor. J Am Soc Nephrol 27: 3022–3034, 2016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer JD: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 109: 1417–1427, 2002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Cousin C, Bracquart D, Contrepas A, Corvol P, Muller L, Nguyen G: Soluble form of the (pro)renin receptor generated by intracellular cleavage by furin is secreted in plasma. Hypertension 53: 1077–1082, 2009 [DOI] [PubMed] [Google Scholar]
  • 4.Kinouchi K, Ichihara A, Sano M, Sun-Wada GH, Wada Y, Kurauchi-Mito A, Bokuda K, Narita T, Oshima Y, Sakoda M, Tamai Y, Sato H, Fukuda K, Itoh H: The (pro)renin receptor/ATP6AP2 is essential for vacuolar H+-ATPase assembly in murine cardiomyocytes. Circ Res 107: 30–34, 2010 [DOI] [PubMed] [Google Scholar]
  • 5.Lu X, Garrelds IM, Wagner CA, Danser AH, Meima ME: (Pro)renin receptor is required for prorenin-dependent and -independent regulation of vacuolar H⁺-ATPase activity in MDCK.C11 collecting duct cells. Am J Physiol Renal Physiol 305: F417–F425, 2013 [DOI] [PubMed] [Google Scholar]
  • 6.Advani A, Kelly DJ, Cox AJ, White KE, Advani SL, Thai K, Connelly KA, Yuen D, Trogadis J, Herzenberg AM, Kuliszewski MA, Leong-Poi H, Gilbert RE: The (Pro)renin receptor: Site-specific and functional linkage to the vacuolar H+-ATPase in the kidney. Hypertension 54: 261–269, 2009 [DOI] [PubMed] [Google Scholar]
  • 7.Ramkumar N, Stuart D, Calquin M, Quadri S, Wang S, Van Hoek AN, Siragy HM, Ichihara A, Kohan DE: Nephron-specific deletion of the prorenin receptor causes a urine concentration defect. Am J Physiol Renal Physiol 309: F48–F56, 2015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Yamaguchi Y, Yonemura S, Takada S: Grainyhead-related transcription factor is required for duct maturation in the salivary gland and the kidney of the mouse. Development 133: 4737–4748, 2006 [DOI] [PubMed] [Google Scholar]
  • 9.Wang F, Lu X, Peng K, Du Y, Zhou SF, Zhang A, Yang T: Prostaglandin E-prostanoid4 receptor mediates angiotensin II-induced (pro)renin receptor expression in the rat renal medulla. Hypertension 64: 369–377, 2014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Gao M, Cao R, Du S, Jia X, Zheng S, Huang S, Han Q, Liu J, Zhang X, Miao Y, Kang J, Gustafsson JA, Guan Y: Disruption of prostaglandin E2 receptor EP4 impairs urinary concentration via decreasing aquaporin 2 in renal collecting ducts. Proc Natl Acad Sci U S A 112: 8397–8402, 2015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Morath R, Klein T, Seyberth HW, Nüsing RM: Immunolocalization of the four prostaglandin E2 receptor proteins EP1, EP2, EP3, and EP4 in human kidney. J Am Soc Nephrol 10: 1851–1860, 1999 [DOI] [PubMed] [Google Scholar]
  • 12.Jensen BL, Stubbe J, Hansen PB, Andreasen D, Skøtt O: Localization of prostaglandin E(2) EP2 and EP4 receptors in the rat kidney. Am J Physiol Renal Physiol 280: F1001–F1009, 2001 [DOI] [PubMed] [Google Scholar]
  • 13.Breyer MD, Davis L, Jacobson HR, Breyer RM: Differential localization of prostaglandin E receptor subtypes in human kidney. Am J Physiol 270: F912–F918, 1996 [DOI] [PubMed] [Google Scholar]
  • 14.Nüsing RM, Treude A, Weissenberger C, Jensen B, Bek M, Wagner C, Narumiya S, Seyberth HW: Dominant role of prostaglandin E2 EP4 receptor in furosemide-induced salt-losing tubulopathy: A model for hyperprostaglandin E syndrome/antenatal Bartter syndrome. J Am Soc Nephrol 16: 2354–2362, 2005 [DOI] [PubMed] [Google Scholar]
  • 15.Pöschke A, Kern N, Maruyama T, Pavenstädt H, Narumiya S, Jensen BL, Nüsing RM: The PGE(2)-EP4 receptor is necessary for stimulation of the renin-angiotensin-aldosterone system in response to low dietary salt intake in vivo. Am J Physiol Renal Physiol 303: F1435–F1442, 2012 [DOI] [PubMed] [Google Scholar]
  • 16.Li JH, Chou CL, Li B, Gavrilova O, Eisner C, Schnermann J, Anderson SA, Deng CX, Knepper MA, Wess J: A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus. J Clin Invest 119: 3115–3126, 2009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Olesen ET, Rützler MR, Moeller HB, Praetorius HA, Fenton RA: Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus. Proc Natl Acad Sci U S A 108: 12949–12954, 2011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Zhang MZ, Sanchez Lopez P, McKanna JA, Harris RC: Regulation of cyclooxygenase expression by vasopressin in rat renal medulla. Endocrinology 145: 1402–1409, 2004 [DOI] [PubMed] [Google Scholar]
  • 19.Yang T, Schnermann JB, Briggs JP: Regulation of cyclooxygenase-2 expression in renal medulla by tonicity in vivo and in vitro. Am J Physiol 277: F1–F9, 1999 [DOI] [PubMed] [Google Scholar]
  • 20.Wang F, Lu X, Peng K, Zhou L, Li C, Wang W, Yu X, Kohan DE, Zhu SF, Yang T: COX-2 mediates angiotensin II-induced (pro)renin receptor expression in the rat renal medulla. Am J Physiol Renal Physiol 307: F25–F32, 2014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Feldt S, Batenburg WW, Mazak I, Maschke U, Wellner M, Kvakan H, Dechend R, Fiebeler A, Burckle C, Contrepas A, Jan Danser AH, Bader M, Nguyen G, Luft FC, Muller DN: Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 51: 682–688, 2008 [DOI] [PubMed] [Google Scholar]
  • 22.Baggaley E, Nielsen S, Marples D: Dehydration-induced increase in aquaporin-2 protein abundance is blocked by nonsteroidal anti-inflammatory drugs. Am J Physiol Renal Physiol 298: F1051–F1058, 2010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Downey P, Sapirstein A, O’Leary E, Sun TX, Brown D, Bonventre JV: Renal concentrating defect in mice lacking group IV cytosolic phospholipase A(2). Am J Physiol Renal Physiol 280: F607–F618, 2001 [DOI] [PubMed] [Google Scholar]
  • 24.Nørregaard R, Madsen K, Hansen PB, Bie P, Thavalingam S, Frøkiær J, Jensen BL: COX-2 disruption leads to increased central vasopressin stores and impaired urine concentrating ability in mice. Am J Physiol Renal Physiol 301: F1303–F1313, 2011 [DOI] [PubMed] [Google Scholar]
  • 25.Jia Z, Liu G, Downton M, Dong Z, Zhang A, Yang T: mPGES-1 deletion potentiates urine concentrating capability after water deprivation. Am J Physiol Renal Physiol 302: F1005–F1012, 2012 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of the American Society of Nephrology : JASN are provided here courtesy of American Society of Nephrology

RESOURCES